Novo Nordisk, Trump and Eli Lilly
Digest more
Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive order to address US drug pricing disparities. Novo Nordisk's semaglutide agents and Eli Lilly's tirzepatide will be significantly cheaper through TrumpRx, a new government platform launching in 2026.
The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.
The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for